Does IL-6 mediate rena manifestations of Castleman's disease?

Internal Medicine

Volumn 41, Issue 12, 2002, Pages 1086-1087

  Fujigaki, Yoshihide ^a   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amyloidosis; Interstitial nephritis; Mesangial proliferative glomerulonephritis; Plasma cell

Indexed keywords

AMYLOID A PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE PHASE RESPONSE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B LYMPHOCYTE; CELL INFILTRATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EDITORIAL; GENE OVEREXPRESSION; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY AMYLOIDOSIS; KIDNEY DISEASE; KIDNEY INTERSTITIUM; LYMPH NODE HYPERPLASIA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; MINIMAL CHANGE GLOMERULONEPHRITIS; MOUSE; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PLASMA CELL; PROLIFERATIVE GLOMERULONEPHRITIS; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSGENIC MOUSE;

EID: 0036971957     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.1086     Document Type: Editorial

References (14)

1. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3: 1202-1216, 1985.
2. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 16: 162-172, 1985.
3. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74: 1360-1367, 1989.
4. Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 86: 7547-7551, 1989.
5. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86: 592-599, 1990.
6. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330: 602-605, 1994.
7. Horii Y, Muraguchi A, Iwano M, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 143: 3949-3955, 1989.
8. Okada N, Miyamoto H, Yoshioka T. Therapeutic effect of cytomedicine on mesangio-proliferative glomerulonephritis in human interleukin-6 transgenic mice. Biol Pharm Bull 20: 255-258, 1997.
9. Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med 122: 395-396, 1995 (letter).
10. Keven K, Nergizoglu G, Ates K, et al. Remission of nephrotic syndrome after removal of localized Castleman's disease. Am J Kidney Dis 35: 1207-1211, 2000.
11. Wu Q, Jinde K, Yanagi H, Endoh M, Sakai H. Acute interstitial nephritis with polyclonal B cell infiltration and development of mantle cell lymphoma. Intern Med 41: 1158-1162, 2002.
12. Sato T, Wakabayashi Y, Hirasawa A, Tashiro Y, Nishikawa T, Chiba S. Multicentric Castleman's disease accompanied with both lymphoid interstitial pneumonia and interstitial nephritis. Rinsho Ketsueki 35: 1322-1328, 1994 (in Japanese, Abstract in English).
13. Frokjaer Thomsen O, Ladefoged J. Castleman's disease with renal infiltration by polyclonal plasma cells. Clin Nephrol 49: 328-330, 1998.
14. Lui SL, Chan KW, Li FK, Cheng IK, Chan TM. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron 78: 323-327, 1998.